Fast Facts

About MedImmune

MedImmune at a Glance
  • Founded in 1988 in Gaithersburg, MD (Washington, DC metro area)
  • Global presence with 2,500 people in the US and UK
  • Robust pipeline of 120 biologics currently in research and development
  • World-class protein engineering and process development capabilities
  • The global biologics research and development arm of AstraZeneca
Our Key Products
  • Synagis® (palivizumab) — the first monoclonal antibody to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Common side effects of Synagis include fever and rash. Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort).
    Important Safety Information for Synagis
    Prescribing Information for Synagis (PDF)
    Prescribing Information for Synagis (Spanish)(PDF)
  • FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) — approved by the FDA in 2012, FluMist Quadrivalent is the first quadrivalent influenza vaccine, containing four strains (two type A strains and two type B strains) to help provide protection against influenza A and B. The company made the decision to convert all U.S. doses of FluMist trivalent to FluMist Quadrivalent; therefore, no trivalent FluMist (Influenza Vaccine Live, Intranasal) will be available in the U.S. for the 2013-2014 season and beyond. The most common side effects of FluMist Quadrivalent are runny or stuffy nose; sore throat; and fever over 100°F.
    Important Safety Information for FluMist Quadrivalent
    Prescribing Information for FluMist Quadrivalent (PDF)
  • Trivalent FluMist (T/LAIV) — a nasally-administered live attenuated influenza vaccine. It is approved in Canada, South Korea, Hong Kong, Macau and Israel for the active immunization of eligible individuals 2-49 (59 in Canada) years of age against influenza disease caused by virus subtypes A and type B contained in the vaccine. Launched in 2003, FluMist was the first advancement in flu technology in over 60 years. The most common side effects of FluMist are runny or stuffy nose; sore throat; and fever over 100°F. In the European Union, the vaccine is approved under the trade name FluenzTM (Live Attenuated, Nasal) for eligible children 2-17 years of age.
Our Leadership

View our Leadership team’s biographies

corporate giving

We provide financial support to the community through charitable donations, event sponsorships, unrestricted educational grants, patient assistance, and more.

Read more
Our Culture our culture

Learn about MedImmune’s unique company culture and the people who make it happen.

Read more